Compare Norwegian Cruise Line Holdings Ltd (NCLH) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Norwegian Cruise Line Holdings Ltd vs Tenet Healthcare Corporation — how do they compare? Norwegian Cruise Line Holdings Ltd trades at $14.89 (market cap $7.07B), while Tenet Healthcare Corporation trades at $269.36 (market cap $20.86B). The key difference: Tenet Healthcare Corporation is far larger — about 3× Norwegian Cruise Line Holdings Ltd's market cap, and Tenet Healthcare Corporation is trading nearer its 52-week high, Norwegian Cruise Line Holdings Ltd nearer its low. Which is the better fit depends on your goals.
| NCLH | THC | |
|---|---|---|
Market Cap | $7.07B | $20.86B |
Sector | Consumer Cyclical | Health |
52-Week High | $26.94 | $280.77 |
52-Week Low | $14.79 | $161.37 |
Enterprise Value | $21.88B | $31.94B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Norwegian Cruise Line Holdings (NCLH) trades at $15.39, down 1.16% with bearish technical signals but attractive valuation metrics including a P/E of 9.33 and P/S of 0.74. The company has beaten earnings estimates for three consecutive quarters, though Q3 2026 faces a higher bar at $0.89 EPS. Recent news highlights fuel cost pressures from rising oil prices, contributing to the stock's recent decline despite positive operational developments like new waterpark openings and fleet expansion.
NCLH presents a value opportunity with strong profitability metrics (36.73% ROE) and analyst consensus price target of $20.25 (32% upside), but faces significant risks from fuel cost volatility, high leverage (debt-to-asset ratio 64.79%), and competitive pressure. The company's turnaround plan focusing on cost controls and fleet optimization must overcome macroeconomic headwinds to drive sustained recovery.
Tenet Healthcare (THC) trades at $259.06, down 2.26% today, with a bearish technical signal but strong fundamentals. The stock exhibits robust profitability with an 82.83% gross margin and 53.31% ROE, supported by three consecutive quarterly EPS beats. Recent news includes a $2.0 billion senior notes offering for refinancing and participation in the Wells Fargo Healthcare Conference.
Outlook remains positive given analyst consensus of 81.25% buy ratings and a $281.44 price target, implying 8.6% upside. Risks include debt refinancing execution and healthcare regulatory pressures, but earnings momentum and valuation multiples below industry averages present a compelling opportunity for value investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
